摘要
近年发现新的肾素-血管紧张素(RAS)轴,即血管紧张素转化酶2-血管紧张素(1-7)-Mas系统。血管紧张素转化酶(ACE)2可有效地将血管紧张素(Ang)Ⅱ降解为Ang(1-7),后者与其受体Mas结合可拮抗AngⅡ的心脏毒性,通过改善心肌缺血再灌注后心肌的收缩功能。
A total of 135 patients with CHF were enrolled in this study (63 males and 72 females, LVEF〈 50M). The patients were divided into three groups: NYHA , NYHAm and NYHA IV group. The levels of plasma-soluble ACE2 in NYHAII, NYHAm and NYHA IV group were (45.59±7.83)U/L, (60. 81-4-16. 41)U/L and (73.30±22. 93)U/L; anti-ACE2 were (47.99±5.88)U/L, (54.31:t:18.82)U/L and(64.91±25.24)U/L; ang- (I-7) were (162.85-4-44.30)ng/L, (291.68±75.50)ng/L and (351.00±90.05)ng/L (all P〈0.05) statistical. Conelusion..Plasma-soluble ACE2, anti-ACE2 and angiotensin (1-7) maybe regarded as new brand and significant biological markers for diagnosis in patients with CHF.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2014年第4期362-364,共3页
Journal of Clinical Cardiology
基金
南京市医学科技发展项目(No:YKK12212)